Skip to main content
Smart Investors Daily
CM

NASDAQ · CMPS

COMPASS Pathways plc

Healthcare · Medical - Care Facilities

$9.01

Down-$0.74 (-8.21%)

Updated Nov 17, 2026, 12:25 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
667.21M
P/E ratio
-2.79
Dividend yield
0.00%
52-week range
$4.88 – $15.87
Volume
2.65M
Avg. volume
1.76M

Price performance · CMPS

CMPS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

CMPS closed at $9.01 after 20 trading sessions, down 18.90% for the selected period.

Last close
$9.01
Period change
-18.90%
Period low
$7.81
Period high
$12.28
Daily close
View OHLC price history
CMPS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$9.01$9.16$8.532$9.012.65M
Nov 12, 2026$8.94$9.335$8.8504$9.122.39M
Nov 11, 2026$9.50$9.50$9.0302$9.302.62M
Nov 10, 2026$9.01$9.4936$8.90$9.252.64M
Nov 9, 2026$8.87$9.28$8.56$9.183.41M
Nov 6, 2026$8.05$8.68$7.99$8.613.76M
Nov 5, 2026$8.46$8.61$7.78$7.815.54M
Nov 4, 2026$8.53$8.88$8.05$8.605.26M
Nov 3, 2026$9.00$9.49$8.47$8.598.85M
Nov 2, 2026$11.71$11.76$7.54$8.4116.85M
Oct 30, 2026$11.822$11.9932$11.27$11.572.18M
Oct 29, 2026$12.37$12.50$11.97$12.191.38M
Oct 28, 2026$11.85$12.31$11.71$12.281.42M
Oct 27, 2026$11.10$11.84$11.00$11.812.28M
Oct 26, 2026$11.285$11.36$10.94$11.051.52M
Oct 23, 2026$11.45$11.515$11.02$11.181.16M
Oct 22, 2026$11.73$11.9699$11.4299$11.631.34M
Oct 21, 2026$12.00$12.12$11.77$11.841.83M
Oct 20, 2026$11.11$12.0441$11.065$11.903.35M
Oct 19, 2026$10.87$11.17$10.81$11.113.28M

Latest CMPS news

The latest Smart Investors Daily articles mentioning CMPS.

CMPS research

Overview

Company profile and research snapshot.

Company profile

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
CMPS recent ratings
DateFirmRatingTarget
Nov 9, 2026HC Wainwright & Co.Buy—
Nov 4, 2026Wells FargoEqual-Weight—
Nov 3, 2026BTIGBuy—
Aug 7, 2026HC Wainwright & Co.Buy—
Aug 6, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Cybin Expects Key Phase III Depression Trial Results This Quarter

Helus Pharma expects results from the first Phase III trial of its experimental adjunctive treatment for major depressive disorder later this quarter, CEO Michael Halstead said at the Guggenheim Healthcare Innovation Conference. The company’s 003 program, a deuterated psilocin treatment, is being s

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.